The chemical class termed C1orf55 Inhibitors encompasses a range of compounds with diverse molecular structures and mechanisms of action, each selected for their ability to influence the pathways and processes in which C1orf55 plays a critical role. This class is defined not by a shared chemical structure, but by a shared target of action: the modulation of C1orf55's involvement in key cellular processes, including DNA repair, RNA splicing, and ribosome biogenesis. The inhibitors in this class operate through various mechanisms, such as interference with protein-protein interactions, inhibition of enzyme activities involved in relevant pathways, or disruption of cellular signaling cascades. These mechanisms allow these inhibitors to indirectly affect the function of C1orf55, despite the absence of direct binding interactions with the protein itself.
The selection of these inhibitors is based on a detailed understanding of the cellular functions and pathways associated with C1orf55. For example, inhibitors that target the DNA damage response are included due to C1orf55's role in inhibiting translesion DNA synthesis and its involvement in the S-phase progression following DNA damage. Similarly, compounds that disrupt pre-mRNA splicing processes are relevant due to SDE2's facilitation of intron excision in pre-mRNA. Inhibitors affecting ribosome biogenesis are also pertinent, given C1orf55's role in this process. The inhibitors span various chemical classes, including small molecules, kinase inhibitors, and others, each chosen for its ability to impact one or more of the cellular processes or pathways in which C1orf55 is implicated. This approach ensures a comprehensive targeting of the protein's multifaceted roles within the cell. In summary, C1orf55 Inhibitors as a chemical class represent a focused effort to modulate the cellular activities of C1orf55 through indirect means. By targeting various steps and components in the pathways where C1orf55 is active, these inhibitors provide a way to influence the protein's function. The diversity of the chemical structures within this class reflects the complexity of the cellular processes involved, necessitating a broad approach to effectively modulate the protein's activity. This class is a testament to the intricate interplay between chemical compounds and biological pathways, showcasing the depth of understanding required to effectively target specific proteins within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib, a PARP inhibitor, could theoretically influence C1orf55's role in DNA damage response, as it impedes DNA repair mechanisms, potentially affecting C1orf55-related pathways. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib is another PARP inhibitor that, similar to Olaparib, may impact C1orf55 function indirectly by altering DNA repair pathways in which C1orf55 is potentially involved. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
As an inhibitor of the spliceosome, Pladienolide B could indirectly affect C1orf55's role in pre-mRNA splicing, especially for genes with weak splice sites. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
As a topoisomerase I inhibitor, Camptothecin could indirectly influence C1orf55's role in DNA repair and replication stress response. | ||||||
UCN-01 | 112953-11-4 | sc-202376 | 500 µg | $251.00 | 10 | |
UCN-01, a kinase inhibitor, might indirectly impact C1orf55 function by modulating signaling pathways related to cell cycle and DNA damage response. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, could indirectly affect C1orf55-related processes by altering protein degradation pathways, potentially impacting C1orf55's degradation post-DNA damage. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide, an immunomodulatory compound, may indirectly influence C1orf55's function by altering cellular signaling pathways involved in DNA repair and replication stress response. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide, known for its broad biological activities, could indirectly affect C1orf55's role in DNA repair and RNA processing by modulating related cellular pathways. | ||||||